Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis
- PMID: 10688712
- DOI: 10.1016/s0190-9622(00)90214-7
Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis
Abstract
Background: CD11a/CD18 comprise subunits of leukocyte function associated antigen (LFA-1), a T-cell surface molecule important in T-cell activation, T-cell emigration into skin, and cytotoxic T-cell function.
Objective: We explored the immunobiologic and clinical effects of treating moderate to severe psoriasis vulgaris with a single dose of humanized monoclonal antibody against CD11a (hu1124).
Methods: This was an open label study with a single dose of hu1124 at doses of 0.03 to 10 mg/kg. Clinical (Psoriasis Area and Severity Index [PASI]) and immunohistologic parameters (epidermal thickness, epidermal and dermal T-cell numbers, and keratinocyte intercellular adhesion molecule 1 [ICAM-1] expression) were followed.
Results: Treatment with hu1124, at doses higher than 1.0 mg/kg (group III), completely blocks CD11a staining for at least 14 days in both blood and psoriatic plaques. At 0.3 to 1.0 mg/kg, T-cell CD11a staining was completely blocked; however, blockade lasted less than 2 weeks (group II). Only partial saturation of either blood or plaque cellular CD11a was observed at doses of hu1124 between 0.01 and 0.1 mg/kg (group I). This pharmacodynamic response was accompanied by decreased numbers of epidermal and dermal CD3(+) T cells, decreased keratinocyte and blood vessel expression of ICAM-1, and epidermal thinning. Statistically significant drops in PASI compared with baseline were observed in group II patients at weeks 3 and 4 and in group III patients at weeks 2 through 10. No significant drop in PASI score was observed in group 1. Adverse events were mild at doses of 0.3 mg/kg or less and included mild chills, abdominal discomfort, headache, and fever. At a single dose of 0.6 mg/kg or higher, headache was the most common dose-limiting toxicity observed.
Conclusion: Targeting CD11a may improve psoriasis by inhibiting T-cell activation, T-cell emigration into the skin, and cytotoxic T-cell function.
Similar articles
-
Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody.Arch Dermatol. 2002 May;138(5):591-600. doi: 10.1001/archderm.138.5.591. Arch Dermatol. 2002. PMID: 12020219 Clinical Trial.
-
The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody.J Am Acad Dermatol. 2001 Nov;45(5):665-74. doi: 10.1067/mjd.2001.117850. J Am Acad Dermatol. 2001. PMID: 11606914 Clinical Trial.
-
Efaluzimab in the treatment of psoriasis.Ann Univ Mariae Curie Sklodowska Med. 2003;58(2):174-8. Ann Univ Mariae Curie Sklodowska Med. 2003. PMID: 15323188 Review.
-
Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis.J Pharmacokinet Biopharm. 1999 Aug;27(4):397-420. doi: 10.1023/a:1020917122093. J Pharmacokinet Biopharm. 1999. PMID: 10826130 Clinical Trial.
-
[Efalizumab].Ann Dermatol Venereol. 2006 Aug-Sep;133(8-9 Pt 1):666-78. doi: 10.1016/s0151-9638(06)70989-9. Ann Dermatol Venereol. 2006. PMID: 17053736 Review. French.
Cited by
-
Fulfilling an unmet need in psoriasis : do biologicals hold the key to improved tolerability?Drug Saf. 2006;29(1):49-66. doi: 10.2165/00002018-200629010-00004. Drug Saf. 2006. PMID: 16454534 Review.
-
Modulating co-stimulation.Neurotherapeutics. 2007 Oct;4(4):666-75. doi: 10.1016/j.nurt.2007.07.006. Neurotherapeutics. 2007. PMID: 17920548 Free PMC article. Review.
-
Structures of the alpha L I domain and its complex with ICAM-1 reveal a shape-shifting pathway for integrin regulation.Cell. 2003 Jan 10;112(1):99-111. doi: 10.1016/s0092-8674(02)01257-6. Cell. 2003. PMID: 12526797 Free PMC article.
-
PBPK-based translation from preclinical species to humans for the full-size IgG therapeutic efalizumab.Front Pharmacol. 2024 Oct 1;15:1418870. doi: 10.3389/fphar.2024.1418870. eCollection 2024. Front Pharmacol. 2024. PMID: 39411068 Free PMC article.
-
Efalizumab in the treatment of psoriasis.Biologics. 2007 Sep;1(3):301-9. Biologics. 2007. PMID: 19707339 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous